Skip to content

Safety and Efficacy of Intra-articular Ozone Injections for Knee Osteoarthritis

Safety and Efficacy of Intra-articular Ozone Injections for Knee Osteoarthritis

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02833545
Enrollment
50
Registered
2016-07-14
Start date
2016-09-01
Completion date
2018-08-01
Last updated
2018-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis Knee

Brief summary

Prospective, Interventional, Non-Randomized, Open Label, Single Group Assignment, Single Center.

Interventions

DEVICEOzone gas

Injection of ozone gas intra articularly

Injection of steroids (diprospan) intra articularly

Sponsors

Rabin Medical Center
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

the outcome assessor was not aware of the therapy administered

Intervention model description

A sequential series of patients receiving steroid injections was compared to a sequential series of patients receiving ozone injections

Eligibility

Sex/Gender
ALL
Age
55 Years to 79 Years
Healthy volunteers
No

Inclusion criteria

* 55 to 79 years of age * Symptomatic Knee osteoarthritis * VAS pain intensity is at least 40 mm on a 100 mm scale * Must be physically and mentally willing and able to comply with post-operative rehabilitation and routinely schedule clinical and radiographic visits.

Exclusion criteria

* Any known tumor of the ipsilateral knee. * Any known infection of the treated knee. * Osteoarthritis of the operated knee Kelgren Lawrence \< grade 2. * Chemotherapy treatment in the past 12 months. * Patients who are sensitive to ozone. * Pregnant women, or breastfeeding women. * Evidence of any significant systemic disease (such as but not limited to HIV infection, hepatitis infection or HTLV infection), known coagulopathies, that might compromise the Subject's welfare. * Substance abuse or alcohol abuse. * Participation in other clinical trials in parallel to this study.

Design outcomes

Primary

MeasureTime frameDescription
Improvement in VAS Pain intensity6 monthsThe outcome measure will be measured according to patient response to the question: during the last week what was your average pain intensity. The response will be measured in millimeters as marked on a 10 cm long line. No pain equals 0 mm and maximal possible pain equals 100mm

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026